Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

{
  "signal_id": "2e9e348f-31a4-1d8f-f6e2-ab5d4aa64fa0",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-08-12T16:02:00+00:00",
  "company": {
    "name": "Tempus AI",
    "domain": "tempus.com"
  },
  "data": {
    "url": "https://www.theglobeandmail.com/investing/markets/stocks/TEM/pressreleases/3808081/is-tempus-ai-worth-buying-as-growth-improves-but-valuation-stays-high/",
    "title": "Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High? - The Globe and Mail",
    "excerpt": "Tempus AI, Inc. TEM is showing faster oncology testing growth, rising data demand and improving adjusted profitability. Management also raised its 2026 revenue outlook after second-quarter results topped expectations. The counterweight is valuation. TEM still trades at a premium to the broader medical sector, while reimbursement gains, cash generation and several growth initiatives require further execution. Tempus raised its 2026 revenue guidance to $1.595-$1.605 billion, representing roughly 25% annual growth. Second-quarter revenues increased 21.6% year over year to $382.5 million. Diagnostics revenues rose 20% to $289.3 million as oncology volume climbed 31%. Data and Applications revenues advanced 28% to $93.2 million, giving Tempus two meaningful growth engines rather than dependence on a single business line. Image Source: Zacks Investment Research TEM trades at 5.5X forward 12-month sales, compared with 5.6X for the Zacks sub-industry, 2.2X for the medical sector and 5.1X for the S&P 500. That valuation is below the stock's five-year median of 7.6X. Image Source: Zacks Investment Research The discount to its sub-industry is modest, while the premium to the sector remains sizable. Investors are therefore paying for continued revenue expansion, reimbursement progress and improving profitability, leaving less room for execution setbacks. FDA approval for tumor-only xT CDx...",
    "summary": "Tempus AI reported a second-quarter GAAP net income of $5.6 million.",
    "planning": false,
    "image_url": "https://www.theglobeandmail.com/pf/resources/assets/meta/twitter-summary-240x240.png?d=943",
    "confidence": 0.9,
    "published_at": "2026-08-12T16:02:00Z",
    "article_sentence": "Second-quarter GAAP net income was $5.6 million, but it included $98.5 million of unrealized gains on marketable securities and $55.6 million of stock compensation expense and related payroll taxes.",
    "amount_normalized": 5600000
  }
}

curl https://signals.autobound.ai/v1/signals/2e9e348f-31a4-1d8f-f6e2-ab5d4aa64fa0 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"tempus.com","limit":20}'